Patricio Atanes

Dr. Patricio Atanes

King's Collage London

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2017 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
Patricio AtanesPatricio Atanes
Patricio Atanes
IRInmaculada Ruz-Maldonado
Inmaculada Ruz-Maldonado
APAttilio Pingitore
Attilio Pingitore
RHRoss Hawkes
Ross Hawkes
BLBo Liu
Bo Liu
SAStefan Amisten
Stefan Amisten
Complement components 3 and 5 (C3 and C5) play essential roles in the complement system, generating C3a and C5a peptides that are best known as chemotactic and inflammatory factors. In this study we characterised islet expression of C3 and C5 complement components, and the impact of C3aR and C5aR1 activation on islet function and viability.

1 December 2021 in Pharmacology & Therapeutics
Verified
Journal Article
Open access
Patricio AtanesPatricio Atanes
Patricio Atanes
TATanyel Ashik
Tanyel Ashik
SPShanta J. Jean Persaud
Shanta J. Jean Persaud
G protein-coupled receptors (GPCRs) are a large family of cell surface receptors that are the targets for many different classes of pharmacotherapy. The islets of Langerhans are central to appropriate glucose homeostasis through their secretion of insulin, and islet function can be modified by ligands acting at the large number of GPCRs that islets express. The human islet GPCRome is not a static entity, but one that is altered under pathophysiological conditions and, in this review, we have compared expression of GPCR mRNAs in human islets obtained from normal weight range donors, and those with a weight range classified as obese. We have also considered the likely outcomes on islet function that the altered GPCR expression status confers and the possible impact that adipokines, secreted from expanded fat depots, could have at those GPCRs showing altered expression in obesity.

17 February 2018 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
Patricio AtanesPatricio Atanes
Patricio Atanes
IRInmaculada Ruz-Maldonado
Inmaculada Ruz-Maldonado
RHRoss Hawkes
Ross Hawkes
BLBo Liu
Bo Liu
MZMin Zhao
Min Zhao
SPShanta J. Jean Persaud
Shanta J. Jean Persaud
Introduction Islets synthesise and secrete numerous peptides, some of which are known to be important regulators of islet function and glucose homeostasis. In this study, we quantified mRNAs encoding all peptide ligands of islet G protein-coupled receptors (GPCRs) in isolated human and mouse islets and carried out in vitro islet hormone secretion studies to provide functional confirmation for the species-specific role of peptide YY (PYY) in mouse islets. Materials and methods GPCR peptide ligand mRNAs in human and mouse islets were quantified by quantitative real-time PCR relative to the reference genes ACTB, GAPDH, PPIA, TBP and TFRC. The pathways connecting GPCR peptide ligands with their receptors were identified by manual searches in the PubMed, IUPHAR and Ingenuity databases. Distribution of PYY protein in mouse and human islets was determined by immunohistochemistry. Insulin, glucagon and somatostatin secretion from islets was measured by radioimmunoassay. Results We have quantified GPCR peptide ligand mRNA expression in human and mouse islets and created specific signalomes mapping the pathways by which islet peptide ligands regulate human and mouse GPCR signalling. We also identified species-specific islet expression of several GPCR ligands. In particular, PYY mRNA levels were ~ 40,000-fold higher in mouse than human islets, suggesting a more important role of locally secreted Pyy in mouse islets. This was confirmed by IHC and functional experiments measuring insulin, glucagon and somatostatin secretion. Discussion The detailed human and mouse islet GPCR peptide ligand atlases will allow accurate translation of mouse islet functional studies for the identification of GPCR/peptide signalling pathways relevant for human physiology, which may lead to novel treatment modalities of diabetes and metabolic disease.


5 December 2017 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
IRInmaculada Ruz-Maldonado
Inmaculada Ruz-Maldonado
APAttilio Pingitore
Attilio Pingitore
BLBo Liu
Bo Liu
Patricio AtanesPatricio Atanes
Patricio Atanes
GHGuo Cai Huang
Guo Cai Huang
SPShanta J. Jean Persaud
Shanta J. Jean Persaud

31 January 2018 in Cellular Physiology and Biochemistry
Verified
Journal Article
Open access
PDF file
Patricio AtanesPatricio Atanes
Patricio Atanes
IRInmaculada Ruz-Maldonado
Inmaculada Ruz-Maldonado
RHRoss Hawkes
Ross Hawkes
BLBo Liu
Bo Liu
SPShanta J. Jean Persaud
Shanta J. Jean Persaud
SAStefan Amisten
Stefan Amisten
Background/Aims: CRISPR-Cas9, a RNA-guided targeted genome editing tool, has revolutionized genetic engineering by offering the ability to precisely modify DNA. GPRC5B is an orphan receptor belonging to the group C family of G protein-coupled receptors (GPCRs). In this study, we analysed the functional roles of the Gprc5b receptor in MIN6 β-cells using CRISPR-Cas9 and transient over-expression of Gprc5b. Methods: The optimal transfection reagent for use in MIN6 β-cells was determined by analysing efficiency of GFP plasmid delivery by cell sorting. A MIN6 β-cell line in which Gprc5b expression was knocked down (Gprc5b KD) was generated using CRISPR-Cas9 technology. Gprc5b receptor mRNA expression, proliferation, apoptosis, Cignal 45-Pathway Reporter Array signalling and western blot assays were carried out using Gpcr5b KD MIN6 β-cells that had been transiently transfected with different concentrations of mouse Gprc5b plasmid to over-express Gprc5b. Results: JetPRIME® was the best candidate for MIN6 β-cell transfection, providing approximately 30% transfection efficiency. CRISPR-Cas9 technology targeting Gprc5b led to stable knock-down of this receptor in MIN6 β-cells and its re-expression induced proliferation and potentiated cytokine- and palmitate-induced apoptosis. The Cignal 45 Reporter analysis indicated Gprc5b-dependent regulation of apoptotic and proliferative pathways, and western blotting confirmed activation of signalling via TGF-β and IFNγ. Conclusion: This study provides evidence of CRISPR-Cas9 technology being used to down-regulate Gprc5b expression in MIN6 β-cells. This strategy allowed us to identify signalling pathways linking GPRC5B receptor expression to β-cell proliferation and apoptosis.